



FOR IMMEDIATE RELEASE

**Rapid Generation of High Antibody-producer Clones Utilizing
Selexis' SURE Technology Platform**

Selexis SA to Present at the European Cell Line Development and Engineering Conference

Geneva, Switzerland – May 05, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic protein manufacturing announced today that it will present “Rapid Generation of High Antibody-producer Clones with MARtech™” at the next European Cell Line Development and Engineering Conference in Zurich, Switzerland (May 23-24, 2006).

Dr. Pierre-Alain, Ph.D., Head of Research and Development at Selexis, will present on Tuesday, May 23, 2006 at 16:40 as part of the “Vector Development and Gene Optimization” track. Selected slides from the lecture, including data on the SURE Technology Platform, which includes the patented MARtech™, will also be available following the meeting.

Presentation Abstract

Rapid generation of high antibody-producer clones with MARtech™

The development of high producer cell lines for manufacturing of recombinant proteins requires the identification of rare clones with defined specificities. We have developed a method that allows the rapid generation of highly productive cell lines that express recombinant human IgG with productivities >50 pcd by placing a MAR element in the vectors. MARtech has the potential to increase stability and proves valuable to shorten the timelines of the selection process.

- more -

SELEXIS EUROPE
18 chemin des Aulx
1228 Plan-les-Ouates
Switzerland

T +41 (0)22 308 93 60
F +41 (0)22 308 93 61

SELEXIS USA
655, Montgomery St. STE 540
San Francisco, CA 94111
USA

T +1 415 273 51 41
F +1 415 837 32 04

Selexis' SURE Technology Platform, which includes the patented MARtech™, is a unique technology that improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. Based on proprietary human MAR (Matrix Attachment Region), MARtech™ enables cell population generation in just four weeks (after transfection) and stable cell line development in ten weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to significantly increase recombinant protein expression in mammalian cells in suspension and in serum-free up to twenty fold.

About Selexis

Headquartered in Geneva, Switzerland, Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services. Selexis offers comprehensive and rapid solutions for the development of stable, high yield mammalian cell lines used in recombinant protein manufacturing.. The Company's unique SURE Technology Platform, which includes Selexis' forth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

About IBC Life Sciences, “Antibody Development and Production” Conference

IBC's pioneering European Cell Line Development and Engineering Conference is the first forum in Europe dedicated exclusively to optimizing cell lines, covering the following topics in detail: Keynote presentations and forward thinking studies by experts from academia and industry; Specific case study examples on current 'best practices' approach to cell line development, choice of host cells, expression system, selection strategies, etc. Interactive discussion session will compare and contrast the different strategies; An in-depth session on cell line validation and regulatory considerations; New reports on optimising expression vector design and translation; An in-depth session on screening and clone selection methods; and End users' comparative evaluation on current most popular technologies. For more information, please visit <http://www.ibc-lifesci.com/celldev/default.asp?src=forthnew>

This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.

MARtech™ is a trademark of Selexis, SA.

MEDIA CONTACT:

Robert Meister
602-953-1716
robert.meister@selexis.com

MORE INFORMATION:

EUROPE
Igor Fisch, Ph.D.
41 (0)22 308 93 60
igor.fisch@selexis.com

UNITED STATES

Cori Gorman, Ph.D., M.B.A.,
415-273-5141
cori.gorman@selexis.com